{rfName}
Ef

Indexed in

License and use

Altmetrics

Grant support

Eugenio Rosado, PhD, and Jordi Bozzo, PhD, CMPP (Grifols) are acknowledged for medical writing and editorial support in the preparation of this manuscript. The authors wish to thank all the patients who contributed to this study. Carmen Altisent is acknowledged for her expert contribution to the acquisition of data. This study was supported by Grifols, manufacturer of the pdVWF/FVIII concentrate (Fanhdi (R)).

Analysis of institutional authors

Jimenez-Yuste, VictorCorresponding AuthorAlvarez-Roman, Maria TeresaAuthor

Share

November 27, 2024
Publications
>
Letters
Hybrid Gold

Efficacy and safety evaluation of Fanhdi(R), a plasma-derived factor VIII/von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study

Publicated to:HAEMOPHILIA. 28 (1): E23-E27 - 2022-01-01 28(1), DOI: 10.1111/hae.14453

Authors: Jimenez-Yuste, Victor; Nunez, Laura; Alvarez-Roman, Maria Teresa; Martin-Salces, Monica; Haya, Saturnino; Federici, Augusto B; Grifols, Carlota; Mairal, Esther; Torres, Mireia; Paez, Antonio

Affiliations

Grifols St Cugat Valles, Sci & Med Affairs, Barcelona, Spain - Author
Grifols, St Cugat Valles, Biosci Res Grp, Barcelona, Spain - Author
Hosp Univ & Politecn La Fe, Hemostasis & Thrombosis Unit, Hematol Serv, Valencia, Spain - Author
Luigi Sacco Hosp, Dept Haematol & Haemotherapy, Milan, Italy - Author
Univ Autonoma Madrid, Hosp Univ La Paz, Dept Hematol & Hemotherapy, Madrid, Spain - Author
See more

Abstract

Keywords

Factor viiiHemophilia aHumansProspective studiesVon willebrand diseasesVon willebrand factor

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal HAEMOPHILIA due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Medicine (Miscellaneous).

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 1.47, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-18, the following number of citations:

  • WoS: 2
  • Scopus: 2
  • Europe PMC: 3

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-18:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 6.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 6 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 4.2.
  • The number of mentions on the social network X (formerly Twitter): 7 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Italy.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (JIMENEZ YUSTE, VICTOR MANUEL) .

the author responsible for correspondence tasks has been JIMENEZ YUSTE, VICTOR MANUEL.